YAP1 Antibody Immunohistochemistry on an FFPE Transitional Cell Carcinoma Tissue
|Intended Use||For In Vitro Diagnostic Use|
|Summary and Explanation|
Yes-Associated Protein 1 (YAP1) is a regulatory protein that binds the Src family tyrosine kinase YES, promotes transcriptional activation of cyclin E and inhibition of caspase-induced apoptosis. YAP1 is found in the cytoplasm, though transported into the nucleus to perform its roles in proliferation and assist in tissue repair and growth. YAP1 is essential for cancer growth, contributing to stem-cell-like features of proliferation and metastasis and inducing these features in neighboring cells. YAP1 may be upregulated or have higher nuclear localization in more malignant and metastatic tumors, as seen in Lung, Breast, Colorectal, Liver, Gastric, Pancreatic, and Brain Cancers.
YAP1 antibody It is frequently overexpressed in Mammary carcinoma, Glioblastoma and Squamous Cell Carcinoma, Pancreatic, Oral, Cervical, Ovarian and Lung Cancers. YAP1 has been found to be expressed in fetal and adult brain regions known to harbor neural progenitor cells but there was little YAP1 immunoreactivity in the adult cerebral cortex. YAP1 protein was also readily detected in the nuclei of human brain tumors. In Medulloblastoma, expression varied between histologic subtypes and was most prominent in Nodular/Desmoplastic tumors. In Gliomas it was frequently expressed in infiltrating Astrocytomas and Oligodendrogliomas, but rarely in Pilocytic Astrocytomas. YAP1 antibody immunoreactivity has been found in the nuclei of tumor cells in 64.8% of Clear Cell Renal Cell Carcinoma (ccRCC) patients, whereas only 24.1% of tumors revealed cytoplasmic YAP1 expression with ccRCC patients having cytoplasmic YAP1 immunoexpression had significantly shorter OS (median = 26.8 months) than patients without cytoplasmic YAP1 and concluded that increased cytoplasmic YAP1 (HR = 4.53) and decreased LATS1 immunoreactivity levels (HR = 0.90) were associated with worse prognosis, being independent prognostic factors. These results suggest that YAP1 and LATS1 can be considered as new prognostic factors in ccRCC.
|Antibody Type||Mouse Monoclonal||Clone||BSB-146|
|Localization||Cytoplasmic, Nuclear||Control||Testis, Placenta, Breast, Fallopian Tube, Transitional Cell Carcinoma, HER2 Negative Breast Cancer|
|Presentation||YAP1 is a mouse monoclonal antibody derived from cell culture supernatant that is concentrated, dialyzed, filter sterilized and diluted in buffer pH 7.5, containing BSA and sodium azide as a preservative.|
|Note: For concentrated antibodies, please centrifuge prior to use to ensure recovery of all product.|